PMID: 9449231Feb 4, 1998Paper

Effects of liposome-encapsulated bisphosphonates on acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells

Life Sciences
R YlitaloS Ylä-Herttuala

Abstract

Bisphosphonates, the drugs used for the treatment of e.g. osteoporosis, inhibit the development of experimental atherosclerosis. When encapsulated in liposomes, they also inactivate macrophages, which have a key role in atherogenesis. We studied the effects of three clinically used bisphosphonates, i.e. clodronate, etidronate and pamidronate, on 1) the viability of mouse peritoneal macrophages and macrophage-like RAW 264 cells, 2) the degradation of 125I-labeled acetylated LDL by RAW 264 cells, and 3) the formation of LDL-derived foam cells in vitro. Liposome-encapsulated clodronate and pamidronate, but not etidronate, decreased the fraction of viable peritoneal macrophages in a concentration-dependent manner, whereas RAW 264 cells were much more resistant to the cytotoxic effects of bisphosphonates. Preincubation with liposomal clodronate and etidronate inhibited in a concentration-dependent manner the degradation of acetylated LDL in RAW 264 cells, but non-cytotoxic concentrations of liposomal pamidronate had only a weak inhibitory effect. The inhibition was more pronounced by liposomal clodronate than by liposomal etidronate. At high concentrations (500 microg protein/ml) of acetylated and aggregated LDL, RAW 264 cells trans...Continue Reading

References

Oct 1, 1978·Analytical Biochemistry·A Hara, N S Radin
Dec 1, 1991·The Journal of Clinical Investigation·M SatoG A Rodan
Apr 1, 1986·Calcified Tissue International·P H Stevenson, J R Stevenson
Jul 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J C KhooD Steinberg
Nov 1, 1980·The Journal of Pathology·T J Chambers
Feb 1, 1996·The Journal of Laboratory and Clinical Medicine·R YlitaloP Ylitalo
Oct 1, 1995·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·D E HughesB F Boyce
Oct 1, 1996·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·M J RogersR G Russell

❮ Previous
Next ❯

Citations

Jun 1, 2005·Biochimica Et Biophysica Acta·Gerd Schmitz, Thomas Langmann
Mar 30, 2002·General Pharmacology·R Ylitalo
Jun 2, 2012·Journal of Neuroinflammation·Hiromi KumamaruSeiji Okada
Jun 20, 2002·Pharmacology & Toxicology·Ritva YlitaloPauli Ylitalo
May 25, 2004·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Hirotake HashibaHiroshi Kogo
Jan 13, 2012·Expert Opinion on Drug Delivery·Kristen BoweyMaryam Tabrizian
Feb 7, 2014·TheScientificWorldJournal·Wen-Chih LiuKuo-Cheng Lu
Oct 13, 2005·Lupus·M BevilacquaM Barbagallo
Mar 25, 2006·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Hirotake HashibaHiroshi Kogo
Jul 10, 2003·Biochemical and Biophysical Research Communications·Dorothea Strobach, Reinhard L Lorenz
Jul 6, 2021·Current Pharmaceutical Design·Rakesh K SahooAmit K Goyal
Mar 30, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Nigel D ToussaintPeter G Kerr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.